<DOC>
	<DOC>NCT00970775</DOC>
	<brief_summary>This is a Phase I, single centre, randomised, double-blind, placebo-controlled, parallel group study to assess the safety, tolerability and pharmacokinetics of AZD2423 following single ascending dose administration to healthy Japanese subjects.</brief_summary>
	<brief_title>AZD2423 Single Ascending Dose Study in Healthy Japanese Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy Japanese male and nonfertile female subjects aged ≥20 to ≤55 years with suitable veins for cannulation or repeated venepuncture. Body weight 4590 kg and Body mass index (BMI) ≥18.0 and ≤27.0 kg/m2 Clinically normal physical findings including supine blood pressure, pulse rate, orthostatic blood pressure, ECG, and laboratory assessments in relation to age, as judged by the Investigator. History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study. Any clinically significant illness/infection or medical/surgical procedure or trauma, as judged by the Principal Investigator, within 3 months of the first administration of investigational product. Frequent use of tobacco or other nicotine containing products. Frequent use is defined as smoking or consumption/intake of nicotine products more than two days per week during the last 12 weeks.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Japanese healthy volunteer</keyword>
	<keyword>AZD2423</keyword>
</DOC>